Deal Announcement

Technology Holdings advises SUAZIO, A Data-Driven Life Sciences and Medtech Strategic Consultancy, on its strategic sale to Namsa

"TH’s impressive track record in the Life Sciences Consulting, Data Science and Digital Transformation spaces was evident through their extensive network of industry buyer and investor relationships and deep understanding of the landscape. Their structured and highly professional sale process, combined with strategic insights and connections to key players in the industry, resulted in numerous offers. Their hard work and commitment to success resulted in an outcome that exceeded our expectations both in terms of valuation and fit. TH did the heavy lifting throughout the process, from creating compelling materials, facilitating extensive buyer/investor meetings, to managing due diligence and negotiations. The team was always responsive and worked hard to negotiate the optimal valuation and structure while guiding us through all the complexities and challenges of the process and consistently providing us with clear advice at each stage. TH truly became an extension of the SUAZIO team, just as they promised! NAMSA's strong heritage in the Life Sciences ecosystem makes them an excellent partner for us."

Christophe Van der Linden
Founder & CEO, SUAZIO

Technology Holdings is pleased to announce that it has acted as the exclusive financial advisor to SUAZIO, a leading data-driven Life Sciences and MedTech consultancy on its strategic sale to NAMSA, the world's leading MedTech CRO, an Archimed portfolio company headquartered in the United States. Founded in 2001 and headquartered in Antwerp, Belgium, with a presence in key European, North American and APAC markets, SUAZIO provides highly specialized data-driven market research, insights, analytics, and consulting services in the Life Sciences and MedTech markets. SUAZIO has developed a research-based, end-to-end ecosystem of complementary consulting services and methodologies for life sciences clients in 5 domains: Customer insights, Product value drivers, Patient journey, Digital healthcare & Economic value proposition. SUAZIO has long term relationships with leading life sciences and medical device companies.

With the acquisition of SUAZIO, NAMSA deepens its research and product development capabilities and increases its global presence to 20 locations across the Americas, Asia and Europe. Dr Christophe Berthoux, CEO of NAMSA said “NAMSA is very enthusiastic about expanding its global strategic consulting services with the addition of SUAZIO. Client insights and precise market research are what power the true value of novel medical technologies and product acceptance. With the SUAZIO Team, NAMSA will expand its client reach even further and strengthen the delivery of its end-to-end development services to the global MedTech industry.”

Christophe Van der Linden, CEO of SUAZIO echoed “With similar values and expertise in providing insights to accelerate MedTech innovation, our services are well-aligned to truly deliver global clients end-to-end development and commercialization solutions that lead to success.”

Vivek Subramanyam, Founder and CEO of Technology Holdings said, “We are proud to have advised SUAZIO on this landmark Life Sciences and MedTech transaction. Christophe and his team have built a truly market leading data driven strategic consultancy. This transaction is our 16th deal in the healthcare and life sciences ecosystem and further demonstrates our expertise as industry leaders in the space. SUAZIO’s capabilities and team are exceptional and we wish them every success in this strategic partnership with NAMSA."

For more information please contact
Vivek Subramanyam
Founder and CEO
+44 77 78 863790
Geeta Ramanathan
Managing Director
+44 7807 173 414

Disclaimer. All products and brand names mentioned are trademarks or registered trademarks of their respective owners. All Trademarks remain the property of their respective holders, and in no way indicates any relationship between Technology Holdings and the holders of said trademarks.